Pharmacological Aspects Of Using Herbal Medicines In The Treatment Of Cough In Children: Pathogenetic Rationale, Mechanisms Of Action, And Clinical Efficacy | Ukrainian Medical Journal

Dunaieva I.P.,Kryvoshapka O.V.,Doroshenko O.M.,Pautina O.I.,Shapoval O.M.

Main
Publications
Pharmacological Aspects Of Using Herbal Medicines In The Treatment Of Cough In Children: Pathogenetic Rationale, Mechanisms Of Action, And Clinical Efficacy

Pharmacological Aspects Of Using Herbal Medicines In The Treatment Of Cough In Children: Pathogenetic Rationale, Mechanisms Of Action, And Clinical Efficacy

March 11, 2026

УДК: 616.24-008.41-053.2-092-085.322.036(048.8)

DOI: 10.32471/umj.1680-3051.274114

Keywords :

cough,

medicinal plants,

mucociliary clearance,

pharmacodynamics,

pharmacology

Specialities :

Pediatrics

Resume

Cough in children is a leading symptom of respiratory tract infections and inflammatory diseases. Given the age-related anatomical and physiological characteristics of the respiratory system, selecting a safe and effective therapy is particularly important. Herbal medicines demonstrate a multifaceted mechanism of action, including secretomotor, mucolytic, anti-inflammatory, bronchodilatory, and immunomodulatory effects. This article provides a detailed overview of the pharmacodynamic and pharmacokinetic characteristics of the medicinal plants Althaea officinalis L., Hedera helix L., Thymus vulgaris L., Glycyrrhiza glabra L., Plantago major L., and Primula veris L., and analyses their clinical rationale in different types of cough in children.

References

1. Shields M.D., Bush A., Everard M.L. et al. (2008) BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax, 63(Suppl. 3): iii1–iii15.
2. Gibson P.G., Chang A.B., Glasgow N.J. et al. (2010) CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian cough guidelines summary statement. Med. J. Aust., 192(5): 265–271.
3. Chang A.B., Glomb W.B. (2006) Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest, 129(Suppl. 1): 260S–283S.
4. Morice A.H., Fontana G.A., Sovijärvi A.R.A. et al. (2004) The diagnosis and management of chronic cough. Eur. Respir. J., 24(3): 481–492.
5. Morice A.H., Millqvist E., Bieksiene K. et al. (2020) ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur. Respir. J., 55(1): 1901136. doi: 10.1183/13993003.01136-2019.
6. Worrall G. (2011) Acute cough in children. Can Fam Physician, 57(3): 315–318.
7. Маркданте К.Д., Клігман Р.М. (2019) Основи педіатрії за Нельсоном: у 2 томах (пер. 8-го англ. вид.). Т. 2. За ред. Березенко В.С., Починок Т.В. С. 151.
8. Устінов О.В. (2018) Алгоритм дії лікаря при наданні медичної допомоги дітям із кашлем. Укр. мед. часопис.
9. Марушко Ю.В. (2015) Мукоактивна терапія при синдромі кашлю у дітей. Укр. мед. часопис, 1(105): 63.
10. Lee K.K., Davenport P.W., Smith J.A. et al. (2021) Global Physiology and Pathophysiology of Cough: Part 1: Cough Phenomenology — CHEST Guideline and Expert Panel Report. Chest, 159: 282–293. doi: 10.1016/j.chest.2020.08.2086.
11. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. (2018) Chest, 153(1): 196–209. doi: 10.1016/j.chest.2017.10.016.
12. Chang A.B., Oppenheimer J.J., Weinberger M. et al. (2017) Etiologies of Chronic Cough in Pediatric Cohorts: CHEST Guideline and Expert Panel Report. Chest, 152(3): 607–617. doi: 10.1016/j.chest.2017.06.006.
13. Chung K.F., Canning B., McGarvey L. (2015) Cough hypersensitivity syndrome as the basis for chronic cough. Pulm. Pharmacol. Ther., 35: 76–80. doi: 10.1016/j.pupt.2015.08.009.
14. Chung K.F., McGarvey L., Holmes P. et al. (2013) Chronic cough as a neuropathic disorder. Lancet Respir. Med., 1(5): 414–422. doi: 10.1016/S2213-2600(13)70043-2.
15. Veldman L.B.M., Belt-Van Zoen E., Baars E.W. (2023) Mechanistic evidence of Andrographis paniculata, Pelargonium sidoides, Echinacea species and a combination of Hedera helix, Primula veris/Primula elatior and Thymus vulgaris/Thymus zygis in the treatment of acute, uncomplicated respiratory tract infections: a systematic literature review and expert interviews. Pharmaceuticals (Basel), 16(9): 1206. doi: 10.3390/ph16091206.
16. Seibel J., Kryshen K., Pongrácz J.E., Lehner M.D. (2018) In vivo and in vitro investigation of anti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts. Pulm. Pharmacol. Ther., 51: 10–17. doi: 10.1016/j.pupt.2018.04.009.
17. Gavrila A.I., Tatia R., Seciu-Grama A.M. et al. (2022) Ultrasound assisted extraction of saponins from Hedera helix L. and an in vitro biocompatibility evaluation of the extracts. Pharmaceuticals (Basel), 15(10): 1197. doi: 10.3390/ph15101197.
18. El-Saber Batiha G., Magdy Beshbishy A., El-Mleeh A. et al. (2020) Traditional uses, bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules, 10(3): 352. doi: 10.3390/biom10030352.
19. Micucci M., Protti M., Aldini R. et al. (2020) Thymus vulgaris L. essential oil solid formulation: chemical profile and spasmolytic and antimicrobial effects. Biomolecules, 10(6): 860. doi: 10.3390/biom10060860.
20. Oliveira J.R., de Jesus Viegas D., Martins A.P.R. et al. (2017) Thymus vulgaris L. extract has antimicrobial and anti-inflammatory effects in the absence of cytotoxicity and genotoxicity. Arch. Oral. Biol., 82: 271–279. doi: 10.1016/j.archoralbio.2017.06.031.
21. Bennett W.D., Henderson A.G., Ceppe A. et al. (2020) Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res., 6: 00269-2020. doi: 10.1183/23120541.00269-2020.
22. Mahboubi M. (2020) Marsh mallow (Althaea officinalis L.) and its potency in the treatment of cough. Complement. Med. Res., 27(3): 174–183. doi: 10.1159/000503747.
23. Bonaterra G.A., Bronischewski K., Hunold P. et al. (2020) Anti-inflammatory and anti-oxidative effects of Phytohustil® and root extract of Althaea officinalis L. on macrophages in vitro. Front. Pharmacol., 11: 290. doi: 10.3389/fphar.2020.00290.
24. Sendker J., Böker I., Lengers I. et al. (2017) Phytochemical characterization of low molecular weight constituents from marshmallow roots (Althaea officinalis) and inhibiting effects of the aqueous extract on human hyaluronidase-1. J. Nat. Prod., 80(2): 290–297. doi: 10.1021/acs.jnatprod.6b00670.
25. Adom M.B., Taher M., Mutalabisin M.F. et al. (2017) Chemical constituents and medical benefits of Plantago major. Biomed. Pharmacother., 96: 348–360. doi: 10.1016/j.biopha.2017.09.152.
26. Naderi A., Mozaffarpur S.A., Shirafkan H. et al. (2024) Effect of Plantago major on cough severity in acute bronchitis: a double-blind randomized clinical trial. Caspian J. Intern. Med., 15(4): 651–658. doi: 10.22088/cjim.15.4.651.
27. Boskabady S.J., Farzameh F., Mohammadnejad K., Boskabady M.H. (2025) The therapeutic effects of Plantago major and its main constituents on respiratory diseases: a narrative review. Naunyn Schmiedebergs Arch. Pharmacol., 398(12): 16693–16711. doi: 10.1007/s00210-025-04276-8.
28. Qabaha K., Abbadi J., Yaghmour R. et al. (2024) Unveiling the antibacterial and antioxidant potential of Hedera helix leaf extracts: recent findings. Can. J. Physiol. Pharmacol., 102(1): 26–32. doi: 10.1139/cjpp-2023-0264.
29. Bach R.O., Schuster A., Bygum A., Paulsen E. (2022) Incognito allergic contact dermatitis from common ivy (Hedera helix L) hiding behind Compositae sensitization. Contact Dermatitis, 86(4): 315–316. doi: 10.1111/cod.14025.
30. Bisht D., Rashid M., Arya R.K.K. et al. (2022) Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: potential pharmacological applications with mechanistic insight. Phytomed. Plus, 2(1): 100206. doi: 10.1016/j.phyplu.2021.100206.
31. Dastagir G., Rizvi M.A. (2016) Glycyrrhiza glabra L. (Liquorice): review. Pak. J. Pharm. Sci., 29(5): 1727–1733.